Research Article

Autoradiographic Mapping of 5-HT\textsubscript{1B/1D} Binding Sites in the Rhesus Monkey Brain Using [\textit{carbonyl-}^{11}\textit{C}]zolmitriptan

Örjan Lindhe,\textsuperscript{1} Per Almqvist,\textsuperscript{2} Mats Kågedal,\textsuperscript{3} Sven-Åke Gustafsson,\textsuperscript{1} Mats Bergström,\textsuperscript{1} Dag Nilsson,\textsuperscript{3} and Gunnar Antoni\textsuperscript{4}

\textsuperscript{1} Uppsala Imanet AB, GE Healthcare, P.O. Box 967, 751 09 Uppsala, Sweden
\textsuperscript{2} Department of Clinical Neuroscience, Karolinska Institute, 171 77 Stockholm, Sweden
\textsuperscript{3} AstraZeneca R&D, 151 85 Södertälje, Sweden
\textsuperscript{4} Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University, Box 574, 75123 Uppsala, Sweden

Correspondence should be addressed to Örjan Lindhe, orjan.lindhe@ge.com

Received 24 May 2011; Revised 11 August 2011; Accepted 12 August 2011

1. Introduction

Triptans act as 5-hydroxytryptamine, 5-HT\textsubscript{1B} and 5-HT\textsubscript{1D}, receptors agonists, and in some cases also activate 5-HT\textsubscript{1F} receptors [1]. Zolmitriptan is a 5-HT\textsubscript{1B/1D} receptor agonist, which has actions at the peripheral [2] and central ends of the trigeminovascular system [3–5]. Zolmitriptan is an effective and well-tolerated acute treatment of migraine [6], with oral and intranasal formulations [7]. Triptans are believed to exert an antimigraine action by activating 5-HT\textsubscript{1} receptors in vascular structures of the brain and meninges [8, 9]. Besides these vascular actions, zolmitriptan has been suggested to act at the trigeminal nucleus and higher pain centers of the brain [4, 5, 10, 11].

In a previous study using [\textit{carbonyl-}^{11}\textit{C}]zolmitriptan ([\textsuperscript{11}C]zolmitriptan), positron emission tomography (PET) imaging was used to describe a rapid uptake of [\textsuperscript{11}C]zolmitriptan into the brain through the blood-brain barrier (BBB) [12]. Zolmitriptan was found in all brain areas studied at concentrations compatible with pharmacological activity. However, no clear difference in the regional uptake of [\textsuperscript{11}C]zolmitriptan, correlating with the known distribution of 5-HT\textsubscript{1B/1D} receptors, was seen.

Autoradiography on whole-hemisphere brain cryosections provides images with high resolution and is therefore a suitable technique for the detailed description of receptor binding sites [13]. Such autoradiographic images can also serve as high resolution anatomical correlates for lower resolution PET and single photon emission computed tomography receptor studies. In the cat brain, [\textsuperscript{3}H]sumatriptan [14] and [\textsuperscript{3}H]zolmitriptan [5] bound to the nucleus tractus solitarius, to the trigeminal nucleus caudalis in the brainstem, and in the dorsal horns of the C1 and C2 cervical spinal cord. Competition studies excluded binding to 5-HT\textsubscript{1A} and 5-HT\textsubscript{1F} and confirmed binding to 5-HT\textsubscript{1B} and 5-HT\textsubscript{1D} receptors, although the relative contribution of these two receptor subtypes to the total binding of [\textsuperscript{3}H]zolmitriptan was not elucidated. In the postmortem human brain stem...
and spinal cord, [3H]sumatriptan showed a distribution of high-density binding similar to that in the cat. The substantia nigra and layer V of the frontal cortex showed high specific binding, followed by the globus pallidus interna and externa nigra and layer V of the frontal cortex. The substantia nigra and spinal cord, [3H]sumatriptan showed a distribution of high-density binding similar to that in the cat. The substantia nigra and layer V of the frontal cortex showed high specific binding, followed by the globus pallidus interna and externa nigra and layer V of the frontal cortex. The substantia nigra and spinal cord, [3H]sumatriptan showed a distribution of high-density binding similar to that in the cat. The substantia nigra and layer V of the frontal cortex showed high specific binding, followed by the globus pallidus interna and externa nigra and layer V of the frontal cortex.

2. Methods

2.1. Chemicals

2.1.1. Zolmitriptan. Zolmitriptan [(S)-4-[[3-[2-(dimethylamino)ethyl]-1Hindol-5-yl][methyl]-2-oxazolidinone] was provided by AstraZeneca (Alderly Park, UK). [Carbonyl-11C]zolmitriptan ([11C]zolmitriptan) was synthesized according to a standard manufacturing procedure developed at Uppsala University. [11C]carbon dioxide was produced by a ditronix MC-17 cyclotron. The [11C]carbon dioxide was converted to [11C]carbon monoxide and used in a selenium mediated carbonylation reaction in an autoclave according to Figure 1. After chromatographic purification the product was dissolved in saline (NaCl 9 mg/mL)/99.5% EtOH, 90/10 v/v.

2.1.2. WAY 100635. WAY 100635 [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl]-N-(2-pyridyl)-cylohex-ane-carboxamide trichloride] (Sigma-Aldrich, St Louis, USA). [Carbonyl-11C]Way 100635 ([11C]WAY) was synthesized as previously described [18].

2.1.3. SB224289. SB224289 [1′-Methyl-5-[[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)bibenzy]H-4-yl]carbonyl]-2,3,6, 7-tetrahydrospiro[furo[2,3-f]indole-3,4′-piperidine hydrochloride], Tocris Cookson Ltd (Bio Nuclear AB, Bromma, Sweden). SB224289 is a selective 5-HT1B receptor antagonist (pKi = 8.2) that displays greater than 60-fold selectivity over 5-HT1D, 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A and 5-HT2C. The affinity for a range of other receptor types (according to the supplier). SB224289 is centrally active following oral administration in vivo.

2.1.4. BRL15572. BRL15572 [(3-[4-(4-Chlorophenyl)piperazin-1-yl]-1,1-diphenyl-2-propanol hydrochloride], Tocris Cookson Ltd (Bio Nuclear AB, Bromma, Sweden). BRL15572 is a selective 5-HT1D antagonist that displays 60-fold selectivity over 5-HT1B and exhibits little or no affinity for a range of other receptor types (according to the supplier).

2.2. Tissue. Brain tissue specimens from Rhesus monkeys (Macaca mulatta) were stored frozen at −70°C. The tissue specimen comprised whole brain hemispheres (right and left), including the cerebrum, cerebellum, and mesencephalon. Coronal cryostat sections (30 μm) from the brain hemispheres were mounted on glass slides and air-dried at room temperature. A total of 120 tissue sections (each section separated by 0.5 mm) were used for the detection of zolmitriptan binding. The slides were stored at −20°C until use.

2.3. Autoradiography. Tissue sections were first pre-incubated in a Tris-buffer (50 mM Tris-HCl buffer pH 7.4, 120 mM NaCl, 5 mM KCl) for 10 minutes at room temperature. The incubations were performed at room temperature in the Tris-buffer with 2 mM CaCl2, 1 mM MgCl2, 0.01% ascorbate, 10 μM pargyline, and with [11C]zolmitriptan. Concentrations of [11C]zolmitriptan and [11C]WAY were 2.5–3 nM for studies of regional distribution and 0.1–30 nM of [11C]zolmitriptan for estimations of Bmax and KD.

For competition of radioligand binding the following compounds were used: zolmitriptan, serotonin, WAY100635, SB224289, and BRL15572. Incubations with the blocking agents were done at concentrations of 0.01, 0.1, 1, and 10 μM. After radiotracer incubation, tissue slides were rinsed in Tris-buffer (3 × 3 minutes), carefully dried at 37°C, and placed on phosphor image plates (Molecular Dynamics, USA) together with reference samples (20 μL aliquots taken from the incubation buffer) for a minimum of 40 minutes exposure, and scanned in a Phosphor Image Model 400S (Molecular Dynamics, USA).

2.4. Anatomical Localization of Binding Sites and Quantification of [11C]zolmitriptan Binding. The autoradiographic images were digitized and superimposed on pictures of the corresponding tissue section by using image analysis (Adobe Photoshop) in order to correlate the areas of tracer binding...
Table 1: The estimated $B_{\text{max}}$ (receptor density) and $K_d$ (affinity of $[^{11}\text{C}]$zolmitriptan) in different brain regions of the Rhesus monkey.

| Brain region          | $B_{\text{max}}$ (pmol/g wet tissue) | $K_d$ (nM) |
|-----------------------|-------------------------------------|------------|
|                       | Mean  | SE    | Mean  | SE    |
| Ventral pallidum      | 17.9  | 2.6   | 2.2   | 1.1   |
| External globus pallidus | 12.2  | 1.4   | 1.3   | 0.6   |
| Substantia nigra      | 11.4  | 1.6   | 1.0   | 0.6   |
| Nucleus accumbens     | 9.5   | 0.6   | 1.8   | 0.4   |
| Visual cortex         | 9.8   | 1.5   | 1.1   | 0.7   |
| Frontal cortex        | 5.2   | 0.8   | 5.1   | 2.1   |
| Cerebellum            | 1.6   | 0.4   | 4.9   | 3.4   |

SE: standard error.

to anatomical structures. Evaluation of the Rhesus monkey brain anatomy was done according to Paxinos et al. [19]. The specific $[^{11}\text{C}]$zolmitriptan binding was calculated as the difference between total and nonspecific binding and expressed in pmol/g wet tissue.

3. Results

3.1. Pharmacology. In all brain areas, $[^{11}\text{C}]$zolmitriptan binding was completely inhibited by the addition of high concentration ($10\, \mu\text{M}$) serotonin at 1 nM tracer concentration and was $\geq 90\%$ inhibited at 3 nM tracer. At this tracer concentration, 0.1 $\mu\text{M}$ zolmitriptan blocked $\geq 90\%$ tracer binding (data not shown). The correlation between incubation time and specific tracer binding was analyzed and found to reach a plateau value at 30 minutes using 30 nM of $[^{11}\text{C}]$zolmitriptan. Extending the incubation time further did not result in increased specific $[^{11}\text{C}]$zolmitriptan binding. By using serotonin and unlabeled zolmitriptan to inhibit binding of $[^{11}\text{C}]$zolmitriptan to brain slices, its targets were proven to be serotonin receptors with specificity for zolmitriptan. Less than 10% of the binding was nonspecific (data not shown).

A semi-quantitative saturation analysis indicated the lowest $K_d$ in the substantia nigra (1.0 nM), followed by the visual cortex (1.1 nM), the external globus pallidus (1.3 nM), the nucleus accumbens (1.8 nM), the ventral pallidum (2.2 nM), the cerebellum (4.9 nM), and the frontal cortex (5.1 nM) (Table 1).

3.2. Distribution of $[^{11}\text{C}]$Zolmitriptan Binding. A regional distribution of $[^{11}\text{C}]$zolmitriptan binding was detected in the Rhesus monkey brain tissue sections, with several high-density binding sites within well-defined anatomical areas (Figure 2). The highest densities of tracer binding were found in (i) the ventral pallidum (17.9 ± 2.6 pmol/g wet tissue), i.e. those parts of the globus pallidus located inferior to the anterior commissure, (ii) in the globus pallidus externa (12.2 ± 1.4 pmol/g wet tissue) and interna, and (iii) in the substantia nigra pars compacta and pars reticulata (11.4 ± 1.6 pmol/g wet tissue) (Figure 2). In addition, high-density binding was located in the visual cortex (9.8 ± 1.5 pmol/g wet tissue), including the calcarine fissure and the lateral cortex of the occipital pole (Figure 2) and in the nucleus accumbens (9.5 ± 0.6 pmol/g wet tissue), that is, where the head of the caudate and the anterior portion of the putamen meet just lateral to the septum pellucidum (Figure 3). $[^{11}\text{C}]$Zolmitriptan binding was low in the frontal cortex (5.2 ± 0.8 pmol/g wet tissue) and virtually absent in the cerebellum (1.6 ± 0.4 pmol/g wet tissue). The distribution and the density of tracer binding were highly consistent in the 8 whole-hemisphere tissue samples used for this study. Neither the pons nor the medulla oblongata was included in the brain tissue specimen used for this study and potential
tracer binding to these parts of the brain stem was not explored.

3.3. Comparing Distribution of $[^{11}C]$Zolmitriptan and $[^{11}C]$/WAY-100635 Binding Sites. High-density binding of $[^{11}C]$/WAY-100635 was present in most neocortical areas of the Rhesus monkey brain, with lower levels in the occipital cortex. The basal ganglia (nucleus caudatus, putamen, pallidum) and thalamus were virtually devoid of 5-HT1A receptor binding (Figure 2). When comparing the distribution of binding sites for $[^{11}C]$zolmitriptan and $[^{11}C]$/WAY-100635 on consecutive tissue sections, there was very limited overlap of binding sites. Anatomical areas with high-density binding of $[^{11}C]$/WAY-100635 had no or very low levels of $[^{11}C]$zolmitriptan binding and vice versa. While there was some overlap of tracer binding in the neocortex, the visual cortex of the occipital lobe showed exclusive $[^{11}C]$zolmitriptan binding. Very low binding was obtained in the cerebellum with either tracer, indicating that the cerebellar cortex was virtually devoid of these binding sites (Figure 2). Competitive binding with WAY 100635 reduced $[^{11}C]$zolmitriptan binding in the substantia nigra and the visual cortex by approximately 20% at 1.0 μM concentration, while tracer binding to other brain areas tested was unaffected (Table 1).

3.4. Distribution of 5-HT1B and 5-HT1D Receptors in the Rhesus Monkey Brain. Differential receptor binding of $[^{11}C]$zolmitriptan was explored (Table 2). The selective 5-HT1B receptor antagonist SB224289 blocked 50–80% of $[^{11}C]$zolmitriptan binding at a 1 μM concentration. $[^{11}C]$zolmitriptan binding was reduced by 70–80% in the substantia nigra, the external globus pallidus and the visual cortex, and by approximately 50% in the nucleus accumbens and the frontal cortex. In contrast, selective 5-HT1D antagonist BRL15572 had much less of an effect in all areas tested, blocking ≤25% of $[^{11}C]$zolmitriptan binding at a 1 μM concentration (Table 2).

![Figure 3: Color-coded autoradiograms of $[^{11}C]$zolmitriptan (top) and $[^{11}C]$/WAY 100635 (bottom) on consecutive brain sections, comparing the distribution of binding sites for the respective tracer. Numbers identify sections where strong $[^{11}C]$zolmitriptan binding is observed. (1) Nucleus accumbens, (2) Ventral pallidum and external globus pallidus (3) Substantia nigra, and (4) Visual cortex. Note the minimal overlap of tracer binding sites.](image)

**Table 2: Displacement of $[^{11}C]$zolmitriptan binding in the nucleus accumbens (NcA), globus pallidus externa (GPE), substantia nigra (SN), visual cortex (VC), and frontal cortex (FC) by selective 5-hydroxytryptamine (HT)1 receptor antagonists at 1 μM concentration. The numbers represent the percentage of receptor displacement compared to control sections.**

| Brain region | 5-HT1A | 5-HT1B | 5-HT1D |
|--------------|--------|--------|--------|
| NcA          | Mean   | SE     | Mean   | SE     | Mean   | SE     |
|              | 0      | 16.0   | 44     | 3.0    | 3      | 1.0    |
| GPE          | 0      | 11.5   | 67     | 1.0    | 12     | 7.5    |
| SN           | 22     | 13.0   | 79     | 0.5    | 9      | 1.5    |
| VC           | 18     | 11.3   | 73     | 2.0    | 25     | 12.1   |
| FC           | 0      | 3.0    | 50     | 9.5    | 3      | 9.0    |

SE: standard error.

4. Discussion

The distribution of $[^{11}C]$zolmitriptan binding sites in the Rhesus monkey brain was consistent with previously reported distribution of 5-HT1B and 5-HT1D receptors in the post-mortem human brain, using whole-hemisphere autoradiography and the radioligand $[^{3}H]$/GR 125743 [16]. Similar to $[^{3}H]$/GR 125743, $[^{11}C]$zolmitriptan binding was highest in the substantia nigra and the globus pallidus. Lower levels were detected in the striatum, with the highest densities in the ventromedial parts. The medial occipital cortex was markedly more labeled compared to the rest of the cerebral cortex, whereas binding densities were very low in the cerebellar cortex and in the thalamus. The lower brain stem and spinal cord were not included in the study, while no information was gained on $[^{11}C]$zolmitriptan binding to the raphe nuclei and trigeminal spinal nuclei.

Previous studies have localised 5-HT1B receptors on serotonergic and nonserotonergic neurons, acting as presynaptic auto-and heteroreceptors, respectively, putatively regulating neurotransmitter release [20–22]. 5-HT1B receptor mRNA has been detected in raphe nuclei, striatum, cerebellum, hippocampus, entorhinal and cingulated cortex, subthalamic nucleus, and nucleus accumbens, but not in the substantia nigra or globus pallidus [23–28]. Autoradiographic visualization of 5-HT1B receptors was found in partly different areas, including dense packing in ventral pallidum, globus pallidus, substantia nigra, dorsal subiculum and moderate dense packing in cerebral cortex, molecular layer of the hippocampus, entopeduncular nucleus, superficial gray layer of the superior colliculus, caudate putamen, and deep nuclei of the cerebellum [29–33]. This mismatch between synthesis and localization is explained by hypothesizing that this receptor is synthesized at a different place (cell body) and transported from there to axon terminals, both in serotonergic and nonserotonergic neurons [34].

Similar to 5-HT1B receptors, binding sites attributed to the 5-HT1D receptor are present in globus pallidus, substantia nigra, caudate and putamen, hippocampus, and cerebral cortex, whereas 5-HT1D receptor mRNA is expressed at low levels in the basal ganglia, dorsal raphe nucleus, and locus ceruleus, indicative of the 5-HT1D receptor being located...
predominantly on axon terminals of both serotonergic and nonserotonergic neurons [35].

New data point to a role of the basal ganglia in migraine. Functional neuroimaging studies have revealed that the substantia nigra (SN) together with the red nucleus (RN) and the occipital cortex (OC) is activated during the attack [36].

Autoradiographic studies of [3H]sumatriptan (5-HT1B, 5-HT1D, 5-HT1F receptors) and of [3H]GR 125743 (5-HT1B and 5-HT1D receptors) in the human brain [16, 37–39] all showed the highest density of binding sites in the visual cortex, substantia nigra, and medial globus pallidus, with the 5-HT1B receptor being the most abundant receptor subtype in the SN and GP [39]. All five regions tested for differential binding of [11C]zolmitriptan to 5-HT1B or 5-HT1D receptors (Table 2), showed 5-HT1B binding to be most abundant, while 5-HT1D receptor binding was increased 2–8-fold in the occipital cortex versus the SN and basal ganglia.

The specific [11C]zolmitriptan binding could only to a small degree (<25%) be displaced by the 5-HT1D antagonist BRL15572, indicating that this receptor is not a major contributor to the efficacy of zolmitriptan. This is consistent with the outcome from a clinical trial of the 5-HT1D receptor antagonist [40] and the data of Varnäs et al. [16].

WAY-100635 is a highly selective, silent 5-HT1A receptor antagonist which binds with high affinity to the 5-HT1A receptor, at both presynaptic and postsynaptic sites [41]. The anatomical distribution of [3H]WAY-100635 binding has been described in detail using large-scale autoradiography on human hemispheric brain cryosections [42]. High densities were found in the hippocampus, superficial layers of the neocortex, and the raphe nuclei. The distribution of [11C]WAY-100635 in the present paper was similar to that of [3H]WAY-100635, with high-density binding in the neocortex and the raphe nuclei of the cynomolgus monkey brain by PET imaging [43]. Consistently, we report high density binding of [11C]WAY-100635 throughout the neocortex, except for the visual cortex of the occipital lobe.

5. Conclusions

In summary, in saturation studies, [11C]zolmitriptan showed specific (90%) binding to a population of high-affinity binding sites in the Rhesus monkey brain. [11C]Zolmitriptan binding showed a regional distribution to defined brain regions with the highest densities in the ventral pallidum, external globus pallidus, substantia nigra, nucleus accumbens, and the visual cortex. In competitive binding studies, a 5-HT1B selective ligand blocked the majority of [11C]zolmitriptan binding across all regions, while 25% of total specific binding was attributable to 5-HT1D receptor binding in the visual cortex. [11C]Zolmitriptan and [11C]WAY-100635 binding sites were differentially distributed with little or no overlap between anatomical areas.

Acknowledgments

The authors thank Elisabeth Bergström Pettermann for expert technical assistance. This study was supported by AstraZeneca.

References

[1] P. J. Goadsby, “The pharmacology of headache,” Progress in Neurobiology, vol. 62, no. 5, pp. 509–523, 2000.
[2] G. R. Martin, A. D. Robertson, S. J. MacLennan et al., “Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT(1B/1D) receptor partial agonist, 311C90 (zolmitriptan),” British Journal of Pharmacology, vol. 121, no. 2, pp. 157–164, 1997.
[3] P. J. Goadsby and L. Edvinsson, “Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (SHT)-1D receptor agonist 311C90,” Headache, vol. 34, no. 7, pp. 394–399, 1994.
[4] P. J. Goadsby and K. L. Hoskin, “Inhibition of trigeminal neurons by intravenous administration of the serotonin (SHT)(1B/D) receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?” Pain, vol. 67, no. 2-3, pp. 355–359, 1996.
[5] P. J. Goadsby and Y. E. Knight, “Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat,” Cephalalgia, vol. 17, no. 3, pp. 153–158, 1997.
[6] K. J. Palmer and C. M. Spencer, “Zolmitriptan,” CNS Drugs, vol. 7, no. 6, pp. 468–479, 1997.
[7] P. J. Goadsby and R. Yates, “Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy,” Headache, vol. 46, no. 1, pp. 138–149, 2006.
[8] J. F. V. Caekenbeke, M. D. Ferrari, C. P. Z Dewit, J. Jansen, and P. R. Saxena, “Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks,” Neurology, vol. 42, no. 8, pp. 1522–1526, 1992.
[9] I. Jansen, L. Edvinsson, A. Mortensen, and J. Olesen, “Sumatriptan is a potent vasoconstrictor of human dural arteries via a 5-HT1-like receptor,” Cephalalgia, vol. 12, no. 4, pp. 202–205, 1992.
[10] M. I. Cumberbatch, R. G. Hill, and R. J. Hargraves, “The effects of 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats,” European Journal of Pharmacology, vol. 362, no. 1, pp. 43–46, 1998.
[11] G. R. Martin, “Pre-clinical pharmacology of zolmitriptan (Zomig®; formerly 311C90), a centrally and peripherally acting SHT1B/1D agonist for migraine,” Cephalalgia, vol. 17, no. 18, Supplement, pp. 4–14, 1997.
[12] M. Bergström, R. Yates, A. Wall, M. Kågedal, S. Svyären, and B. Långström, “Blood-brain barrier penetration of zolmitriptan—modelling of positron emission tomography data,” Journal of Pharmacokinetics and Pharmacodynamics, vol. 33, no. 1, pp. 75–91, 2006.
[13] B. Långström, P. E. Andren, Ö Lindhe, M. Svedberg, and H. Hall, “In vitro imaging techniques in neurodegenerative diseases,” Molecular Imaging and Biology, vol. 9, no. 4, pp. 161–175, 2007.
[14] A. Mills and G. R. Martin, “Autoradiographic mapping of [3H]sumatriptan binding in cat brain stem and spinal cord,” European Journal of Pharmacology, vol. 280, no. 2, pp. 175–178, 1995.
[15] M. E. Castro, J. Pascual, T. Romon, C. Del Arco, E. Del Olmo, and A. Pazos, “Differential distribution of [3H]sumatriptan binding sites (5-HT(1B), 5-HT(1D) and 5-HT(1F) receptors) in human brain: focus on brainstem and spinal cord,” Neuropharmacology, vol. 36, no. 4-5, pp. 535–542, 1997.
[16] K. Varnäs, H. Hall, P. Bonaventure, and G. Sedvall, “Autoradiographic mapping of 5-HT1B and 5-HT1D receptors in the post mortem human brain using [3H]GR 125743,” Brain Research, vol. 915, no. 1, pp. 47–57, 2001.
A. Pazos and J. M. Palacios, “Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors,” Brain Research, vol. 346, no. 2, pp. 205–230, 1985.

Y. Sari, “Serotonin1B receptors: from protein to physiological function and behavior,” Neuroscience and Biobehavioral Reviews, vol. 28, no. 6, pp. 565–582, 2004.

Y. Sari, M. C. Miquel, M. J. Brisorgueil et al., “Cellular and subcellular localization of 5-hydroxytryptamine(1B) receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies,” Neuroscienc, vol. 88, no. 3, pp. 899–915, 1999.

U. Boschert, D. A. Amara, L. Segu, and R. Hen, “The mouse 5-hydroxytryptamine(1B) receptor is localized predominantly on axon terminals,” Neuroscience, vol. 58, no. 1, pp. 167–182, 1994.

A. T. Bruinsvels, J. M. Palacios, and D. Hoyer, “Autoradiographic characterisation and localisation of 5-HT(1D) compared to 5-HT(1B) binding sites in rat brain,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 334, no. 1, pp. 1–7, 1986.

M. Göthert, P. Propping, H. Bönisch, M. Brüss, and M. M. Nöthen, “Genetic variation in human 5-HT receptors: potential pathogenetic and pharmacological role,” Annals of the New York Academy of Sciences, vol. 861, pp. 26–30, 1998.

G. Maura and M. Raiteri, “Cholinergic terminals in rat hippocampus possess 5-HT(1B) receptors mediating inhibition of acetylcholine release,” European Journal of Pharmacology, vol. 129, no. 3, pp. 333–337, 1986.

P. Bonaventure, P. Voorn, W. H. M. L. Luyten, M. Jurzak, A. Schotte, and J. E. Leyens, “Detailed mapping of serotonin 5-HT(1B) and 5-HT(1D) receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: clues for function,” Neuroscience, vol. 82, no. 2, pp. 469–484, 1998.

A. T. Bruinsvels, B. Landwehrmeyer, E. L. Gustafson et al., “Localization of 5-HT(1B), 5-HT(1Da), 5-HT(1E) and 5-HT(1F) receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: clues for function,” Tissue and Cell, vol. 27, no. 5, pp. 302–3024, 1992.